数字化健康管理对急性冠脉综合征PCI术后患者临床结局的影响 --多中心、随机、对照研究

注册号:

Registration number:

ChiCTR2400086452 

最近更新日期:

Date of Last Refreshed on:

2024-07-02 09:40:25 

注册时间:

Date of Registration:

2024-07-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

数字化健康管理对急性冠脉综合征PCI术后患者临床结局的影响 --多中心、随机、对照研究

Public title:

The impact of digital health management on clinical outcomes of patients with acute coronary syndrome after PCI--a multicenter, randomized, controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

数字化健康管理对急性冠脉综合征PCI术后患者临床结局的影响 --多中心、随机、对照研究

Scientific title:

The impact of digital health management on clinical outcomes of patients with acute coronary syndrome after PCI--a multicenter, randomized, controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王春娟 

研究负责人:

雷新军 

Applicant:

Wang Chunjuan 

Study leader:

Lei Xinjun 

申请注册联系人电话:

Applicant telephone:

+86 135 2054 3737

研究负责人电话:

Study leader's
telephone:

+86 137 0029 8310

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ziyeziye2008@163.com

研究负责人电子邮件:

Study leader's E-mail:

xinjunlei@xjtu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市高新区沣惠南路34号摩尔中心

研究负责人通讯地址:

陕西省西安市雁塔区雁塔西路277号

Applicant address:

Mo'er Center, No. 34 Fenghui South Road, High tech Zone, Xi'an, Shaanxi,China

Study leader's address:

No.277 West Yanta Road, Yanta District, Xi'an, Shaanxi, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安鹫一卓越软件技术开发公司

Applicant's institution:

Xi'an Jiuyi Excellent Software Technology Development Company

研究负责人所在单位:

西安交通大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Xi 'an Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024伦审医研字第(134)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学医学院第一附属医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-04 00:00:00

伦理委员会联系人:

杨瑾

Contact Name of the ethic committee:

Yang jin

伦理委员会联系地址:

陕西省西安市雁塔区雁塔西路277号

Contact Address of the ethic committee:

No.277 West Yanta Road, Yanta District, Xi'an, Shaanxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 29 8532 3473

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安交通大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Xi 'an Jiaotong University

研究实施负责(组长)单位地址:

陕西省西安市雁塔区雁塔西路277号

Primary sponsor's address:

No.277 West Yanta Road, Yanta District, Xi'an, Shaanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安交通大学第一附属医院

具体地址:

陕西省西安市雁塔区雁塔西路277号

Institution
hospital:

The First Affiliated Hospital of Xi 'an Jiaotong University

Address:

No.277 West Yanta Road, Yanta District, Xi'an, Shaanxi, China

经费或物资来源:

国家教育部

Source(s) of funding:

the Ministry of National Education

研究疾病:

急性冠脉综合征  

Target disease:

acute coronary syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索构建基于智能手机专用软件的成体系、可外推的ACS患者PCI术后院外数字化管理模式,并评估在患者院外康复过程中,与现行的单一常规术后随访管理模式相比较,数字化管理模式结合常规术后随访管理模式是否更有利于患者的康复。  

Objectives of Study:

To Explore the construction of a systematic and extrapolatable digital management model for ACS patients after PCI based on smartphone specific software, and evaluate whether digital management model combined with conventional postoperative follow-up management model is more conducive to patient rehabilitation compared to the current single conventional postoperative follow-up management model in the process of patient rehabilitation outside the hospital.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

a、伴有严重心肝肾功能障碍、免疫功能障碍及急慢性严重的其他系统疾病; b、PCI术后发生严重夹层、休克、巨大血肿等严重并发症者; c、伴有出血性疾病、恶性肿瘤者; d、未经治疗的室性心动过速、严重心力衰竭、难以控制的高血压或低血压; e、有心脏外科手术史者; f、精神疾病、严重认知功能障碍或无自主行为能力的患者; g、无法为试验目的操作智能手机(如视力、听力或灵活性障碍)者; h、居住地缺乏互联网接入者; i、拒绝签署知情同意书的患者。

Exclusion criteria:

a. accompanied by severe heart, liver and kidney dysfunction, immune dysfunction, and other serious acute and chronic systemic diseases; b. Patients with severe complications such as dissection, shock, and massive hematoma after PCI surgery; c. Patients with hemorrhagic diseases and malignant tumors; d. Untreated ventricular tachycardia, severe heart failure, uncontrolled hypertension or hypotension; e. have a history of cardiac surgery; f. Patients with mental illness, severe cognitive impairment or lack of autonomous behavior ability; g. Patients who are unable to operate smartphones for experimental purposes (such as vision, hearing, or flexibility disorders); h. Lack of Internet access in residence; i. Patients who refuse to sign informed consent forms.

研究实施时间:

Study execute time:

From 2024-08-01 00:00:00 To 2027-08-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-01 00:00:00 To 2026-01-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

683

Group:

Experimental group

Sample size:

干预措施:

患者出院后1年内在接受现行常规术后随访管理的基础上还接受数字化平台管理

干预措施代码:

Intervention:

Within one year after discharge, in addition to receiving current routine postoperative follow-up management, they also received digital platform management.

Intervention code:

组别:

对照组

样本量:

683

Group:

control group

Sample size:

干预措施:

患者出院后1年内接受现行常规术后随访管理

干预措施代码:

Intervention:

Received current routine postoperative follow-up management within 1 year after discharge

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Xi 'an Jiaotong University

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

青海 

市(区县):

 

Country:

China

Province:

Qinghai

City:

单位(医院):

青海省心脑血管病专科医院 

单位级别:

三级甲等 

Institution
hospital:

Qinghai Provincial Cardiovascular and Cerebrovascular Disease Specialized Hospital

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

青海 

市(区县):

 

Country:

China

Province:

Qinghai

City:

单位(医院):

青海省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Qinghai Provincial People's Hospital

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

甘肃 

市(区县):

 

Country:

China

Province:

Gansu

City:

单位(医院):

兰州大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Lanzhou University

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

甘肃 

市(区县):

 

Country:

China

Province:

Gansu

City:

单位(医院):

天水市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

First People's Hospital of Tianshui

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

通用环球西电集团医院 

单位级别:

三级甲等 

Institution
hospital:

XIAN XD GROUP HOSPITAL

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

新疆 

市(区县):

 

Country:

China

Province:

Xinjiang

City:

单位(医院):

新疆医科大学第五附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Fifth Affiliated Hospital of Xinjiang Medical University

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

内蒙古 

市(区县):

 

Country:

China

Province:

Neimenggu

City:

单位(医院):

内蒙古自治区人民医院 

单位级别:

三级甲等 

Institution
hospital:

Inner Mongolia Autonomous Region People's Hospital

Level of the institution:

grade A tertiary hospital

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

南华大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Nanghua Hospital,University of south China

Level of the institution:

grade A tertiary hospital

测量指标:

Outcomes:

指标中文名:

出院后1年主要不良心脑血管事件(MACCE)发生率

指标类型:

主要指标

Outcome:

The incidence of major adverse cardiovascular and cerebrovascular events (MACCE) in the first year after discharge

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全因死亡发生率

指标类型:

次要指标

Outcome:

The incidence of all-cause mortality

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心源性死亡发生率

指标类型:

次要指标

Outcome:

The incidence of cardiogenic death

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非致死性心肌梗死发生率

指标类型:

次要指标

Outcome:

The incidence of non fatal myocardial infarction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再次血运重建发生率

指标类型:

次要指标

Outcome:

The incidence of revascularization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心功能指标

指标类型:

次要指标

Outcome:

Cardiac function indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

quality of life score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心理健康评分

指标类型:

次要指标

Outcome:

Psychological health score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生化指标

指标类型:

次要指标

Outcome:

Biochemical indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非致死性卒中发生率

指标类型:

次要指标

Outcome:

The incidence of non fatal stroke

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与本研究的统计分析人员通过计算机专业软件产生随机分配表。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized numbers generated by statistical analysts who did not participate in this study through a computer.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放标签,但对研究评估者隐藏患者分组信息。

Blinding:

Open-label study,but hide grouping for research evaluators

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Temporarily not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病历记录表(CRF)进行数据采集,将所得数据记录在Excel表格中。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF is used for data collection, and Excel is used for management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-07-02 09:39:17